Indolcarboxamide Is a Preclinical Candidate for Treating Multidrug-Resistant Tuberculosis-Reference-Cited by-同舟云学术

Indolcarboxamide Is a Preclinical Candidate for Treating Multidrug-Resistant Tuberculosis

Published:2013-12-04 Issue:214 Volume:5 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Rao Srinivasa P. S.¹,Lakshminarayana Suresh B.¹,Kondreddi Ravinder R.¹,Herve Maxime¹,Camacho Luis R.¹,Bifani Pablo¹,Kalapala Sarath K.¹,Jiricek Jan¹,Ma Ng L.¹,Tan Bee H.¹,Ng Seow H.¹,Nanjundappa Mahesh¹,Ravindran Sindhu¹,Seah Peck G.¹,Thayalan Pamela¹,Lim Siao H.¹,Lee Boon H.¹,Goh Anne¹,Barnes Whitney S.²,Chen Zhong²,Gagaring Kerstin²,Chatterjee Arnab K.²,Pethe Kevin¹,Kuhen Kelli²,Walker John²,Feng Gu¹,Babu Sreehari³,Zhang Lijun³,Blasco Francesca¹,Beer David¹,Weaver Margaret⁴,Dartois Veronique¹,Glynne Richard²,Dick Thomas¹,Smith Paul W.¹,Diagana Thierry T.¹,Manjunatha Ujjini H.¹

Affiliation:

1. Novartis Institute for Tropical Diseases, Singapore 138670, Singapore.

2. Genomics Institute of the Novartis Research Foundation, San Diego, CA 92121, USA.

3. Novartis Pharmaceuticals, Shanghai 201203, China.

4. Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.

Abstract

The small-molecule indolcarboxamide is a potential drug candidate for treating multidrug-resistant tuberculosis.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference50 articles.

1. World Health Organization (WHO) Global Tuberculosis Report (WHO Press Geneva 2012); http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf.

2. Clinical Pharmacology and Lesion Penetrating Properties of Second- and Third-Line Antituberculous Agents Used in the Management of Multidrug-Resistant (MDR) and Extensively-Drug Resistant (XDR) Tuberculosis

3. A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis

4. Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis

5. OPC-67683, a Nitro-Dihydro-Imidazooxazole Derivative with Promising Action against Tuberculosis In Vitro and In Mice

Cited by 143 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mycobacterial biofilms: Understanding the genetic factors playing significant role in pathogenesis, resistance and diagnosis;Life Sciences;2024-08

2. Organocatalytic Fischer Indolization Using the 2,2′-Biphenol/ B(OH)3 System;Synlett;2024-05-17

3. Identification and optimization of pyridine carboxamide-based scaffold as a drug lead for Mycobacterium tuberculosis;Antimicrobial Agents and Chemotherapy;2024-02-07

4. S288T mutation altering MmpL3 periplasmic domain channel and H-bond network: a novel dual drug resistance mechanism;Journal of Molecular Modeling;2024-01-15

5. The Mycobacterium tuberculosis MmpL3 inhibitor MSU-43085 is active in a mouse model of infection;Microbiology Spectrum;2024-01-11